|
|
|
|
|
|
Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market developed to restore vision in retinal diseases like retinitis pigmentosa. |
|
|
|
|
|
| The Role For Decentralization In Condensing Timelines | Webinar | MRN - Medical Research Network | Discover how prioritizing patient-centricity and decentralization in clinical trials optimizes timelines and budgets, with expert insights into recruitment, attrition, and implementation strategies. |
|
|
| Key To A Faster, More Flexible Clinical Trial Process | Application Note | Revvity Signals Software, Inc. | See how a single, integrated data analytics and visualization platform, supported by an experienced partner, can help you move your investigational product to market more quickly. |
|
|
|
|
|
| It's no secret that on-going research aims to improve the efficacy and specificity of non-viral approaches for genetic engineering. But the field is rapidly evolving with research aimed at improving transfection efficiency, targeting, and safety profiles of non-viral delivery systems. Join Cell & Gene Live to discuss the most notable approaches and recent breakthroughs as well as promising non-viral vectors used in clinical trials. Attendance is free thanks to the support of MaxCyte. |
|
|
CLINICAL TRIALS SOLUTIONS |
|
|
|
|
|
|
|
By Annie Lamontagne, Blake Bergam, and Uzma Shoukat-Mumtaz, Dark Horse Consulting | These recommendations guide cell and gene therapy companies through the selection process for innovative tools, technology, and services to enable forward compatibility through all stages of development. |
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
